by Richard Cruse | Jan 26, 2023 | News
ProFactor Pharma’s executive directors, Jaymin Amin, CEO, and Richard Cruse, CFO, visited PT Bio Farma (Persero) (BFI) who recently licensed PFP’s patented process to make low-cost Factor VIII treatment for Haemophilia A. Jaymin met with BFI’s CEO, Mr. Honesti Basyir,...
by Richard Cruse | Oct 19, 2022 | News
The patented process to make low-cost treatment for Haemophilia A, developed by Scottish biotechnology company ProFactor Pharma Ltd (PFP), has taken an important step closer to market. The successful completion of a Product Development, Technology Transfer and...
by Richard Cruse | Sep 20, 2022 | News
ProFactor Pharma is pleased to announce completion of a further investment round. The investment will enable PFP to progress the company’s clinical stage Recombinant Human Factor VIII to market and to engage with commercial licensing opportunities. The funding...
by Richard Cruse | Nov 24, 2021 | News
Published on November 23, 2021 By Deborah Johnson Interview: Ending the haemophilia drug shortage Jaymin Amin, CEO of ProFactor Pharma (PFP), discusses the company’s life-changing, and lifesaving, work. PFP says it has developed a low-cost production process for...
by Richard Cruse | Mar 31, 2021 | News
ProFactor Pharma Ltd (PFP) the developer of a unique, ultra high yielding cell line for the manufacture of recombinant human factor VIII (rhVIII), is pleased to announce the recent issuance of Indian Patent No. 361851 and Eurasian Patent No 529615EA. This patent...
